1. Academic Validation
  2. A Disintegrin and Metalloproteinase Domain 17 Regulates Colorectal Cancer Stem Cells and Chemosensitivity Via Notch1 Signaling

A Disintegrin and Metalloproteinase Domain 17 Regulates Colorectal Cancer Stem Cells and Chemosensitivity Via Notch1 Signaling

  • Stem Cells Transl Med. 2016 Mar;5(3):331-8. doi: 10.5966/sctm.2015-0168.
Rui Wang 1 Xiangcang Ye 1 Rajat Bhattacharya 1 Delphine R Boulbes 1 Fan Fan 1 Ling Xia 1 Lee M Ellis 2
Affiliations

Affiliations

  • 1 Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • 2 Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA lellis@mdanderson.org.
Abstract

Evidence is accumulating for the role of Cancer Stem Cells (CSCs) in mediating chemoresistance in patients with metastatic colorectal Cancer (mCRC). A disintegrin and metalloproteinase domain 17 (ADAM17; also known as tumor necrosis factor-α-converting Enzyme [TACE]) was shown to be overexpressed and to mediate cell proliferation and chemoresistance in CRC cells. However, its role in mediating the CSC phenotype in CRC has not been well-characterized. The objective of the present study was to determine whether ADAM17 regulates the CSC phenotype in CRC and to elucidate the downstream signaling mechanism that mediates Cancer stemness. We treated established CRC cell lines and a newly established human CRC cell line HCP-1 with ADAM17-specific small interfering RNA (siRNA) or the synthetic peptide inhibitor TAPI-2. The effects of ADAM17 inhibition on the CSC phenotype and chemosensitivity to 5-fluorouracil (5-FU) in CRC cells were examined. siRNA knockdown and TAPI-2 decreased the protein levels of cleaved Notch1 (Notch1 intracellular domain) and HES-1 in CRC cells. A decrease in the CSC phenotype was determined by sphere formation and ALDEFLUOR assays. Moreover, TAPI-2 sensitized CRC cells to 5-FU by decreasing cell viability and the median lethal dose of 5-FU and increasing Apoptosis. We also showed the cleavage and release of soluble Jagged-1 and -2 by ADAM17 in CRC cells. Our studies have elucidated a role of ADAM17 in regulating the CSC phenotype and chemoresistance in CRC cells. The use of drugs that inhibit ADAM17 activity might increase the therapeutic benefit to patients with mCRC and, potentially, those with other solid malignancies.

Keywords

A disintegrin and metalloproteinase domain 17; Cancer stem cells; Chemosensitivity; Colorectal cancer; Jagged-1; Notch1.

Figures
Products